Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

578
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
578
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

398
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
398
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

839
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
839
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

547
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
547
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.6K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Closing the implementation gap: the Joint Action on Cardiovascular Diseases and Diabetes (JACARDI) as a proof of-concept for Europe's Safe Hearts Plan.

International journal of public health·2026
Same author

Which Systematic Review Software Works Best? A Practical Comparison

Journal of the Medical Library Association : JMLA·2026
Same author

Rationale and design of the Pre-MYO project: a precision-medicine platform for myocarditis diagnosis and management.

ESC heart failure·2026
Same author

Strengthening non-communicable diseases monitoring systems in Europe through a multistakeholder collaborative approach: a key priority for advancing data-driven policymaking.

The Lancet regional health. Europe·2026
Same author

Mental health and cardiovascular disease consensus statement: key messages.

European heart journal·2025
Same author

A circadian checkpoint relocates neutrophils to minimize injury.

The Journal of experimental medicine·2025

Related Experiment Video

Updated: Mar 27, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.4K

The cardiovascular polypill: clinical data and ongoing studies.

José M Castellano1, Héctor Bueno2, Valentín Fuster3

  • 1Centro Nacional de Investigaciones Cardiovasculares (CNIC) Carlos III, Madrid, Spain; Hospital Universitario Montepríncipe, HM Hospitales, Madrid, Spain; Mount Sinai Cardiovascular Institute, New York, USA.

International Journal of Cardiology
|January 10, 2016
PubMed
Summary

Improving cardiovascular disease secondary prevention requires better medication adherence. The polypill, a single-pill combination, shows promise in enhancing adherence and convenience for patients, potentially reducing healthcare costs and improving outcomes.

Keywords:
Cardiovascular polypillPrimary preventionSecondary preventionTreatment adherence

More Related Videos

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.7K
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.1K

Related Experiment Videos

Last Updated: Mar 27, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.4K
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.7K
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.1K

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Pharmacology

Background:

  • Secondary prevention of cardiovascular disease (CVD) relies on medical therapy and lifestyle changes.
  • Many patients do not achieve target treatment goals for blood pressure, lipids, and glycemic control.
  • Poor medication adherence is a significant barrier to effective CVD management and contributes to substantial healthcare costs.

Purpose of the Study:

  • To explore the role of polypills in improving medication adherence and cardiovascular risk modification.
  • To highlight the potential of polypills in enhancing patient convenience and reducing healthcare expenditure.

Main Methods:

  • Review of studies examining medical therapy adherence in coronary heart disease.
  • Analysis of the concept and development of polypills for cardiovascular risk reduction.
  • Consideration of randomized clinical trials demonstrating polypill effects on risk factors and adherence.

Main Results:

  • Approximately 50% of patients fail to meet treatment targets for key cardiovascular risk factors.
  • Non-adherence to medication is a major contributor to poor outcomes and increased healthcare costs.
  • Polypills offer a strategy to improve convenience and adherence, with demonstrated effects on risk factors.

Conclusions:

  • Polypills represent a promising approach to enhance medication adherence and simplify cardiovascular risk management.
  • Further research, including major trials, is ongoing to confirm the impact of polypills on hard clinical outcomes.